Pharma BD Deal Intelligence
Merck's $400M acquisition of IOmet Pharma for its IDO/TDO inhibitor pipeline was wiped out by the class-wide epacadostat failure that killed IDO1 inhibitors industry-wide. The lead compound reached only Phase 1b alongside Keytruda before quietly disappearing from Merck's pipeline, with no approved product or disclosed revenue.
Merck's $400M bet on IOmet's IDO/TDO inhibitors was wiped out by the class-wide epacadostat failure; no approved product, no disclosed revenue, and the lead asset quietly vanished from Merck's pipeline.
Full analysis, sources & comparables →Factual coverage framing the deal as part of Merck's broader immuno-oncology strategy: acquiring IOmet's pipeline of IDO and TDO inhibitors designed to…
Seeking Alpha framed the deal as Merck improving its standing in 'a subsector of cancer immunotherapy that could grow in popularity,' noting that 'if IDO/TDO…
FierceBiotech reported the ECHO-301 epacadostat+Keytruda failure crashed Incyte (-20%) and NewLink (-45%) and triggered an industry-wide retreat from IDO…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Merck acquired UK-based IOmet Pharma, gaining preclinical pipeline of IDO, TDO, and dual IDO/TDO inhibitors to bolster immuno-oncology development program. Financial terms undisclosed; press reports estimate ~$400M total deal value. Strategic combination potential with Keytruda.
Merck's $400M bet on IOmet's IDO/TDO inhibitors was wiped out by the class-wide epacadostat failure; no approved product, no disclosed revenue, and the lead asset quietly vanished from Merck's pipeline.
Assessment window: 10yr post-close.
IDO1 and TDO are rate-limiting enzymes in tryptophan catabolism. Their overexpression in glioma, melanoma, lung, ovarian, and colorectal tumors depletes tryptophan and elevates kynurenine in the tumor microenvironment, suppressing T-cell activity. Combining IDO/TDO inhibition with PD-1 blockade was hypothesized to convert non-responders into responders by removing a parallel immunosuppressive mechanism.
When Merck acquired IOmet in January 2016 (terms undisclosed; Pharma Manufacturing cited a ~$400M figure), the IDO race was led by Incyte's epacadostat in a high-profile combination program with Keytruda (ECHO-301), Bristol-Myers Squibb's BMS-986205 (acquired from Flexus Biosciences for $800M upfront in early 2015), and NewLink Genetics' indoximod and navoximod. IOmet brought Merck a wholly owned, in-house IDO/TDO/dual-inhibitor portfolio at preclinical stage, hedging its dependence on the Incyte alliance. The thesis collapsed in April 2018 when ECHO-301 showed epacadostat added no PFS benefit to Keytruda in metastatic melanoma; Incyte's stock fell >20%, NewLink's ~45%, and BMS, Genentech, and others scaled back or terminated programs. The IOmet preclinical portfolio appears to have been quietly de-prioritized in the wake of the class-wide reset, though Merck has not formally disclosed termination of these specific programs.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co., Inc. / IOmet Pharma Ltd. (this deal) | 2016 | $400M | 23 |
| Merck & Co., Inc. / Afferent Pharmaceuticals, Inc. | 2016 | $1.2B | 23 |
| Merck & Co., Inc. / cCAM Biotherapeutics Ltd. | 2015 | $605M | 17 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
← Browse all deals · How we score deals
More: 2016 deals · Merck & Co., Inc. deals · Oncology deals